Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Columbia University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
University of Florida
Cellectar Biosciences, Inc.
Nuvation Bio Inc.
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Turning Point Therapeutics, Inc.
Dana-Farber Cancer Institute
Virginia Commonwealth University
Second Affiliated Hospital, School of Medicine, Zhejiang University